Safety, Reactogenicity and Immunogenicity of an H5N1 VLP

Update Il y a 5 ans
Reference: NCT00519389

Woman and Man

Extract

This is a Phase I/IIa randomized, double-blind, placebo-controlled study to evaluate the safety, reactogenicity, and immunogenicity of 3 potencies (dosages) of H5N1 VLP vaccine or placebo in healthy adults 18 to 40 years of age.


Inclusion criteria

  • Pandemic influenza

Links